Dupilumab - Prurigo nodularis
You are here : Home > Formulary Search > Dupilumab - Prurigo nodularis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Non Formulary
Formulations :
- Subcutaneous injection (sc)
Formulary Status :
Restrictions / Comments :
Documents :
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Dupilumab
Indication :
Prurigo nodularis
Group Name :
Keywords :
Brand Names Include :
Dupixent
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Dupilumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Prurigo nodularis.
- No records returned.
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that dupilumab for Prurigo Nodularis will be given a NON-FORMULARY traffic light status following publication of NICE TA955
Dupilumab is not recommended, by NICE, within its marketing authorisation, for treating this indication